Reaction Details Report a problem with these data
Target
Tyrosine-protein kinase Fes/Fps
Ligand
BDBM50448785
Substrate
n/a
Meas. Tech.
ChEMBL_1294432 (CHEMBL3129258)
IC50
5.0±n/a nM
Citation
Huang, Q; Johnson, TW; Bailey, S; Brooun, A; Bunker, KD; Burke, BJ; Collins, MR; Cook, AS; Cui, JJ; Dack, KN; Deal, JG; Deng, YL; Dinh, D; Engstrom, LD; He, M; Hoffman, J; Hoffman, RL; Johnson, PS; Kania, RS; Lam, H; Lam, JL; Le, PT; Li, Q; Lingardo, L; Liu, W; Lu, MW; McTigue, M; Palmer, CL; Richardson, PF; Sach, NW; Shen, H; Smeal, T; Smith, GL; Stewart, AE; Timofeevski, S; Tsaparikos, K; Wang, H; Zhu, H; Zhu, J; Zou, HY; Edwards, MP Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib. J Med Chem 57:1170-87 (2014) [PubMed] Article
More Info.:
Target
Name:
Tyrosine-protein kinase Fes/Fps
Synonyms:
FES | FES_HUMAN | FPS | Tyrosine-protein kinase FES | Tyrosine-protein kinase Fes/Fps
Type:
Enzyme
Mol. Mass.:
93498.99
Organism:
Homo sapiens (Human)
Description:
P07332
Residue:
822
Sequence:
MGFSSELCSPQGHGVLQQMQEAELRLLEGMRKWMAQRVKSDREYAGLLHHMSLQDSGGQSRAISPDSPISQSWAEITSQTEGLSRLLRQHAEDLNSGPLSKLSLLIRERQQLRKTYSEQWQQLQQELTKTHSQDIEKLKSQYRALARDSAQAKRKYQEASKDKDRDKAKDKYVRSLWKLFAHHNRYVLGVRAAQLHHQHHHQLLLPGLLRSLQDLHEEMACILKEILQEYLEISSLVQDEVVAIHREMAAAAARIQPEAEYQGFLRQYGSAPDVPPCVTFDESLLEEGEPLEPGELQLNELTVESVQHTLTSVTDELAVATEMVFRRQEMVTQLQQELRNEEENTHPRERVQLLGKRQVLQEALQGLQVALCSQAKLQAQQELLQTKLEHLGPGEPPPVLLLQDDRHSTSSSEQEREGGRTPTLEILKSHISGIFRPKFSLPPPLQLIPEVQKPLHEQLWYHGAIPRAEVAELLVHSGDFLVRESQGKQEYVLSVLWDGLPRHFIIQSLDNLYRLEGEGFPSIPLLIDHLLSTQQPLTKKSGVVLHRAVPKDKWVLNHEDLVLGEQIGRGNFGEVFSGRLRADNTLVAVKSCRETLPPDLKAKFLQEARILKQYSHPNIVRLIGVCTQKQPIYIVMELVQGGDFLTFLRTEGARLRVKTLLQMVGDAAAGMEYLESKCCIHRDLAARNCLVTEKNVLKISDFGMSREEADGVYAASGGLRQVPVKWTAPEALNYGRYSSESDVWSFGILLWETFSLGASPYPNLSNQQTREFVEKGGRLPCPELCPDAVFRLMEQCWAYEPGQRPSFSTIYQELQSIRKRHR